Chris McLeod is a Managing Partner at Elm Street Ventures. Previously, Chris was Co-Founder and CEO of AxioMx, an antibody development acquired by Abcam plc in 2015. Throughout his career, he has demonstrated expertise in growing companies through strategic collaborations, innovative marketing, and new product development. McLeod served as President and Chief Executive Officer of 454 Life Sciences from February 2005 through September 2011, and managed the integration with Roche Diagnostics following its acquisition in 2007. He was Executive Vice President from November 1999, where he oversaw bioinformatics, strategic business development, and collaborative research. 

Prior to joining 454 Life Sciences, McLeod spent over two years as Chief Executive Officer of Havas Interactive (formerly Cendant Software), a leading international software developer. He earned his B.S. Magna Cum Laude with a dual major in economics and engineering and applied science from Yale University and his M.S. in management from the Sloan School of Management at Massachusetts Institute of Technology. Chris serves on the boards of Sacred Heart University and the CT Yankee Council, Boy Scouts of America.